Perspective Therapeutics Inc. Common Stock (CATX)
Stock · AMEX · Health Care
$2.17as of 10/16/2026
Price chart
Active signals
Resistance level
$2.9
Industry
Biotechnology: Pharmaceutical Preparations
CATX Signal Track Record
How signals performed across all stocks →What CATX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 48 | +5.8% | 56% | September 18, 2026 |
| Bollinger Band Breakout | 27 | +3.3% | 52% | August 11, 2026 |
| Bollinger Band Breakdown | 21 | -2.2% | 48% | October 6, 2026 |
| 200-Day Moving Average TouchActive now | 14 | -14.4% | 14% | August 19, 2026 |
| Any 20-session window (baseline) | -2.0% | 47% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CATX
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previous…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 163
Fundamentals
- 1-day range
- $2.15$2.34
- Market cap
- $338.72M
- P/E (trailing)
- —
- P/E (forward)
- -2.09
- EPS (trailing)
- $-1.33
- Dividend yield
- —
- Beta
- 1.86
- Avg. volume
- 1.58M
52-week range
$1.96$6.16
Next earnings: November 9, 2026 · EPS estimate $-0.25
Forecasts
14 analyst ratings
Buy 90%
Hold 10%
Sell 0%
1-year price forecast
High
$18
+729.5%
Median
$13
+499.1%
Low
$5
+130.4%
Perspective Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CATXPerspective Therapeutics Inc. Common Stock$2.17▼ 7.26%Market cap $338.72MP/E —$1.96$6.16
- LYELLyell Immunopharma Inc. Common Stock$8.12▼ 0.85%Market cap $348.21MP/E —$7.2$45
- FHTXFoghorn Therapeutics Inc. Common Stock$1.85▼ 2.12%Market cap $327.04MP/E —$1.79$7.61
- GALTGalectin Therapeutics Inc. Common Stock$3.62▼ 2.43%Market cap $324.74MP/E —$2.03$7.13
- ZNTLZentalis Pharmaceuticals Inc. Common Stock$2.13▼ 4.91%Market cap $355.93MP/E —$1.21$6.95
- NATRNature's Sunshine Products Inc. Common Stock$12.64▲ 0.00%Market cap $357.68MP/E 12.66$12.8$28.14
- DMACDiaMedica Therapeutics Inc. Common Stock$7.57▼ 5.85%Market cap $364.79MP/E —$5.25$10.42
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CATX Perspective Therapeutics Inc. Common Stock | $338.72M | — | $2.17 | ▼ 7.26% | $1.96$6.16 |
| LYEL Lyell Immunopharma Inc. Common Stock | $348.21M | — | $8.12 | ▼ 0.85% | $7.2$45 |
| FHTX Foghorn Therapeutics Inc. Common Stock | $327.04M | — | $1.85 | ▼ 2.12% | $1.79$7.61 |
| GALT Galectin Therapeutics Inc. Common Stock | $324.74M | — | $3.62 | ▼ 2.43% | $2.03$7.13 |
| ZNTL Zentalis Pharmaceuticals Inc. Common Stock | $355.93M | — | $2.13 | ▼ 4.91% | $1.21$6.95 |
| NATR Nature's Sunshine Products Inc. Common Stock | $357.68M | 12.66 | $12.64 | ▲ 0.00% | $12.8$28.14 |
| DMAC DiaMedica Therapeutics Inc. Common Stock | $364.79M | — | $7.57 | ▼ 5.85% | $5.25$10.42 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength?Yahoo · 10/9/2026
- Perspective Therapeutics Receives FDA Fast Track Designation For Development Of PSV359 For Adult Patients With Locally Advanced Unresectable And/Or Metastatic Fibroblast Activation Protein-Positive Solitary Fibrous Tumorsbenzinga · 10/8/2026
- Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous TumorsYahoo · 10/8/2026
- Perspective Therapeutics Receives FDA Fast Track Designation For Development Of PSV359 For Adult Patients With Locally Advanced Unresectable And/Or Metastatic Fibroblast Activation Protein-Positive Solitary Fibrous TumorsBenzinga · 10/8/2026
- Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical SymposiumYahoo · 10/7/2026
- BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price TargetBenzinga · 10/7/2026
- Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026Yahoo · 10/2/2026
- Perspective Therapeutics Reveals Acceptance Of [212Pb]VMT01 Data For Presentation At SITC 2026Benzinga · 10/2/2026
- Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market SessionBenzinga · 9/21/2026
Insider Activity
Insider Actions →Acquired
0
Disposed
517.9K
- Lantheus Alpha Therapy, LLC · September 4, 2026 · Sale167.1K @ $3.15
- Lantheus Alpha Therapy, LLC · September 3, 2026 · Sale80.8K @ $3.11
- Lantheus Alpha Therapy, LLC · September 2, 2026 · Sale42.1K @ $3.11
- Lantheus Alpha Therapy, LLC · September 1, 2026 · Sale35.8K @ $3.12
- Lantheus Holdings, Inc. · September 1, 2026 · Sale35.8K @ $3.12
- Lantheus Alpha Therapy, LLC · August 31, 2026 · Sale78.1K @ $3.14
- Lantheus Holdings, Inc. · August 31, 2026 · Sale78.1K @ $3.14
Institutional Ownership
March 31, 2026
- Total shares held
- 77.26M
- Total value held
- $321.68M
- Institutional holders
- 132
Top holders this quarter
- Unknown7.92M
- Unknown6.34M
- Unknown6.05M
- Unknown5.35M
- Unknown4.67M
- Unknown4.38M
- Unknown4.05M
- Unknown3.64M
- Unknown3.16M
- Unknown3.13M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
CATX included in pre-market movers list
Perspective Therapeutics was listed among stocks moving lower in Monday's pre-market session. The company is currently trading near its 52-week low, with an RSI of 32.3 indicating oversold conditions. Analysts maintain an average price target of $12.29, which is significantly higher than the current market price.
CATX included in pre-market movers list. Perspective Therapeutics was listed among stocks moving lower in Monday's pre-market session. The company is currently trading near its 52-week low, with an RSI of 32.3 indicating oversold conditions. Analysts maintain an average price target of $12.29, which is significantly higher than the current market price.